Can-Fite BioPharma (CANF) Competitors $1.96 -0.01 (-0.51%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends CANF vs. INKT, TNXP, PLUR, GOVX, LGVN, LPCN, MRKR, EQ, HCWB, and NAIIShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include MiNK Therapeutics (INKT), Tonix Pharmaceuticals (TNXP), Pluri (PLUR), GeoVax Labs (GOVX), Longeveron (LGVN), Lipocine (LPCN), Marker Therapeutics (MRKR), Equillium (EQ), HCW Biologics (HCWB), and Natural Alternatives International (NAII). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. MiNK Therapeutics Tonix Pharmaceuticals Pluri GeoVax Labs Longeveron Lipocine Marker Therapeutics Equillium HCW Biologics Natural Alternatives International MiNK Therapeutics (NASDAQ:INKT) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership. Does the MarketBeat Community favor INKT or CANF? MiNK Therapeutics received 11 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 75.00% of users gave MiNK Therapeutics an outperform vote while only 6.78% of users gave Can-Fite BioPharma an outperform vote. CompanyUnderperformOutperformMiNK TherapeuticsOutperform Votes1575.00% Underperform Votes525.00% Can-Fite BioPharmaOutperform Votes46.78%Underperform Votes5593.22% Do analysts rate INKT or CANF? MiNK Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 855.88%. Can-Fite BioPharma has a consensus price target of $18.00, suggesting a potential upside of 818.37%. Given MiNK Therapeutics' higher probable upside, equities analysts plainly believe MiNK Therapeutics is more favorable than Can-Fite BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more risk & volatility, INKT or CANF? MiNK Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Do institutionals & insiders have more ownership in INKT or CANF? 2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 19.7% of MiNK Therapeutics shares are owned by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has stronger valuation & earnings, INKT or CANF? Can-Fite BioPharma has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$22.46M-$0.39-1.74Can-Fite BioPharma$740K9.38-$7.63M-$1.79-1.09 Is INKT or CANF more profitable? Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -189.14% Can-Fite BioPharma N/A N/A N/A Does the media favor INKT or CANF? In the previous week, MiNK Therapeutics had 5 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 8 mentions for MiNK Therapeutics and 3 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.34 beat MiNK Therapeutics' score of 0.21 indicating that Can-Fite BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCan-Fite BioPharma beats MiNK Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Brownstone ResearchMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.Click here and I’ll tell you everything you need to know. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$6.94M$6.99B$5.38B$20.15BDividend YieldN/A8.15%5.13%3.50%P/E Ratio-1.0911.05105.0444.55Price / Sales9.38361.961,233.1217.75Price / CashN/A52.5940.4121.28Price / Book1.1110.377.094.71Net Income-$7.63M$153.60M$119.65M$986.85M7 Day PerformanceN/A4.60%2.25%3.76%1 Month Performance-26.04%-6.29%-2.34%4.65%1 Year Performance-7.03%33.41%33.97%27.72% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma1.8312 of 5 stars$1.96-0.5%$18.00+818.4%-8.0%$6.94M$740,000.00-1.098Analyst DowngradeNews CoverageINKTMiNK Therapeutics3.2329 of 5 stars$0.71+2.2%$6.50+822.0%-34.6%$27.88MN/A-1.7730TNXPTonix Pharmaceuticals2.7457 of 5 stars$0.20-2.3%$53.50+26,703.6%-98.8%$27.40M$7.77M0.00103Analyst ForecastGap DownPLURPluri0.0799 of 5 stars$4.89+4.0%N/A-1.2%$27.19M$330,000.00-0.78150Gap UpGOVXGeoVax Labs2.7991 of 5 stars$2.88+6.7%$13.25+360.1%-61.5%$27.19M$80,000.000.0017Analyst RevisionLGVNLongeveron1.7732 of 5 stars$1.89+1.1%$8.00+323.3%-90.1%$27.14M$710,000.00-0.3023LPCNLipocine2.0536 of 5 stars$5.00flat$10.00+100.0%+108.5%$26.74M$7.92M-6.5810Analyst ForecastMRKRMarker Therapeutics3.5384 of 5 stars$2.99+1.4%$19.00+535.5%+15.7%$26.68M$3.31M0.0060EQEquillium3.2482 of 5 stars$0.74+2.7%$5.00+576.3%+42.2%$26.19M$36.08M-5.1840Gap DownHCWBHCW Biologics1.074 of 5 stars$0.69-2.8%N/A-30.3%$26.10M$2.84M-0.7140News CoverageNAIINatural Alternatives International0.341 of 5 stars$4.15-2.4%N/A-31.5%$25.73M$113.80M-2.88290News Coverage Related Companies and Tools Related Companies MiNK Therapeutics Alternatives Tonix Pharmaceuticals Alternatives Pluri Alternatives GeoVax Labs Alternatives Longeveron Alternatives Lipocine Alternatives Marker Therapeutics Alternatives Equillium Alternatives HCW Biologics Alternatives Natural Alternatives International Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CANF) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANF Stock Alerts